Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 11/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226304 | 0.88 | MAP2K1 (0.54) | MAP2K1KDRMAPK14EGFRERBB2 | |
| SCHEMBL1228138 | 0.83 | KDR (0.55) | MAP2K1KDRMAPK14 | |
| SCHEMBL27634063 | 0.78 | KDR (0.39) | MAP2K1KDRMAPK14 | |
| SCHEMBL12728844 | 0.78 | KDR (0.39) | MAP2K1KDRMAPK14 | |
| SCHEMBL4046095 | 0.76 | EGFR (0.60) | MAP2K1KDRMAPK14EGFRERBB2 | |
| SCHEMBL12729492 | 0.75 | MAPK14 (0.60) | KDRMAPK14 | |
| SCHEMBL4046229 | 0.75 | KDR (0.48) | MAP2K1KDRMAPK14EGFRERBB2 | |
| SCHEMBL13755654 | 0.75 | MAPK14 (0.49) | KDRMAPK14 | |
| SCHEMBL16716631 | 0.75 | MAP2K1 (0.56) | MAP2K1KDRMAPK14EGFRERBB2 | |
| SCHEMBL1227597 | 0.74 | MAP2K1 (0.55) | MAP2K1KDRMAPK14EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108594-A1 | PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPYLPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108594-A1 | PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPYLPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN | MAPK1, MAP3K1, MAP3K5 | MAP2K1 56/4885KDR 2182/4885MAPK14 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.